Review on Favipiravir Application Uses and Adverse Effect During Covid-19


  • Sejal Kalra Lloyd Institute of Management and Technology, Plot No 11, Knowledge Park II, Greater Noida, Uttar Pradesh 201306
  • Sethi V. A. Lloyd Institute of Management and Technology, Plot No 11, Knowledge Park II, Greater Noida, Uttar Pradesh 201306
  • Parashar A. K. Lloyd Institute of Management and Technology, Plot No 11, Knowledge Park II, Greater Noida, Uttar Pradesh 201306



The global outbreak of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has spurred an urgent search for effective antiviral medications. Favipiravir (FVP), an antiviral medicine, has emerged as a promising solution to halt the replication and spread of the virus within the human body. In this comprehensive review, we delve into the molecular mechanisms of FVP, exploring its ability to combat the coronavirus family, with SARS-CoV-2 as the primary focus. The coronavirus family, notorious for causing respiratory illnesses ranging from the common cold to severe acute respiratory syndrome (SARS), poses a significant threat to global public health. FVP, known for its anti-viral properties, has garnered attention for its potential to address the COVID-19 crisis. This review meticulously examines the harmful effects associated with FVP, shedding light on its safety margins and the evolving understanding of its deteriorating state. Despite its popularity as a go-to anti-COVID-19 drug, it is crucial to understand the nuances surrounding FVP to optimize its usage and mitigate potential risks. As the world grapples with the ongoing pandemic, understanding the intricacies of FVP's efficacy and safety profile becomes paramount. This review aims to contribute to the growing body of knowledge surrounding FVP, providing insights that are vital for healthcare professionals, researchers, and policymakers in their collective efforts to combat the global health crisis.


Download data is not yet available.


Metrics Loading ...


Covid-19, Anti-viral, Favipiravir , Viral disease, SARS-CoV-2, Favi-pill.




How to Cite

Sejal Kalra, V. A., S., & A. K., P. (2023). Review on Favipiravir Application Uses and Adverse Effect During Covid-19. International Journal of Newgen Research in Pharmacy & Healthcare, 1(2), 174–180.





Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis I-G, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med [Internet]. 2021;21(2):167–79. Available from: DOI:

Gülhan R, Eryüksel E, Gülçebi İdriz Oğlu M, Çulpan Y, Toplu A, Kocakaya D, et al. Pharmacokinetic characterization of favipiravir in patients with COVID‐19. Br J Clin Pharmacol [Internet]. 2022;88(7):3516–22. Available from: DOI:

Abdallah IA, El-Behairy MF, Ahmed RM, Fayed MAA. The anti-COVID-19 drug Favipiravir: Degradation, Method development, Validation, NMR/LC–MS characterization, and In-vitro safety evaluation. Chem Pap [Internet]. 2022;76(10):6415–26. Available from: DOI:

Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis [Internet]. 2021;102:501–8. Available from: DOI:

Marzouk HM, Rezk MR, Gouda AS, Abdel- Megied AM. A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling. Microchem J [Internet]. 2022;172(106917):106917. Available from: 7 DOI:

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res [Internet]. 2020;30(3):269–71. Available from: DOI:

Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: A prospective, multicenter, open-label, randomized controlled clinical trial. Front Pharmacol [Internet]. 2021;12:683296. Available from: DOI:

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering.

Study Group Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.

Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther [Internet]. 2015;53(10):866– 74. Available from: DOI:

Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? J Virus Erad [Internet]. 2020;6(2):45–51. Available from: 6640(20)30016-9 DOI:

Favipiravir and Remdesivir Appear to Be Relatively Unencumbered with Drug-Drug Interactions - Anaesthesia Patient Safety Foundation.

Gillenwater S, Rahaghi F, Hadeh A. Remdesivir for the treatment of covid-19 - preliminary report. N Engl J Med [Internet]. 2020;383(10):992. Available from: DOI:

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med [Internet]. 2020;382(24):2327–36. Available from: DOI:

Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess [Internet]. 2016;20(42):1–242. Available from: DOI:

Kourentas A, Gajewska M, Lin W, Dhareshwar SS, Steib-Lauer C, Kulkarni S, et al. Establishing the safe space via physiologically based biopharmaceutics modeling. Case study: Fevipiprant/QAW039. AAPS J [Internet]. 2023;25(1):25. Available from: DOI:

Doi Y, Ishihara T, Banno S, Ando M, Kondo M, Favipiravir Observational Study. Favipiravir for symptomatic COVID-19: A nationwide observational cohort study. J Infect Chemother [Internet]. 2023;29(2):150–6. Available from: DOI:

Chuah CH, Chow TS, Hor CP, Cheng JT, Ker HB, Lee HG, et al. Efficacy of early treatment with favipiravir on disease progression among high-risk patients with Coronavirus disease 2019 (COVID-19): A randomized, open-label clinical trial. Clin Infect Dis [Internet]. 2022;75(1):e432–9. Available from: DOI:

Sánchez-Hernández A, García-Gómez D, Pérez Pavón JL, Rodríguez-Gonzalo E. Simultaneous determination of favipiravir and surrogates of its metabolites by means of heart-cutting bidimensional liquid chromatography (2D-LC). Anal Biochem [Internet]. 2024;684(115375):115375. Available from: DOI:

Yamani HZ, El Azab NF. First electropolymerized carbidopa-based molecularly imprinted film: Disposable electrochemical sensor for monitoring of anti- COVID-19 drug favipiravir in human plasma. Microchem J [Internet]. 2024;196(109572):109572. Available from: 2 DOI:

Siripongboonsitti T, Muadchimkaew M, Tawinprai K, Issaranon O, Meepholkij W, Arttawejkul P, et al. Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV). Sci Rep [Internet]. 2023;13(1). Available from: DOI:

Zajacova A, Dvorackova E, Casas-Mendez LF, Brixi A, Kotowski T, Havlin J, et al. Use of favipiravir as a broad-spectrum virostatic drug in lung transplant recipients. In: Transplantation. European Respiratory Society; 2023. DOI:

Chavalertsakul K, Petnak T, Boonsarngsuk V, Sangkanuparph S, Thammavaranucupt K, Kirdlarp S, et al. Remdesivir versus favipiravir in hospitalized patients with moderate COVID-19 pneumonia: A propensity scorematched retrospective cohort study. In: Respiratory infections and bronchiectasis. European Respiratory Society; 2023. DOI:

Challenger E, Penchala SD, Hale C, Fitzgerald R, Walker L, Reynolds H, et al. Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma. J Pharm Biomed Anal [Internet]. 2023;233(115436):115436. Available from: DOI:

Endah Endriastuti N, Ekowati H, Suryoputri MW. The evaluation of favipiravir utilization and clinical outcome of inpatients covid-19 in Secondary Care Hospital, central java. Indones J Pharm [Internet]. 2023; Available from: DOI:

Sharaf YA, Abd El-Fattah MH, El-Sayed HM, Hegazy MA. Spectrophotometric determination of favipiravir in presence of its acid hydrolysis product. BMC Chem [Internet]. 2023;17(1). Available from: DOI:

Hadiatussalamah -. -., Andayani TM, Sari IP. Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta. J Manaj Dan Pelayanan Farm (J Manag Pharm Pract) [Internet]. 2023;13(3). Available from: DOI:

Hayden FG, Lenk RP, Epstein C, Kang LL. Oral favipiravir exposure and pharmacodynamic effects in outpatient adults with acute influenza. J Infect Dis [Internet]. 2023; Available from: DOI:

Seydi E, Rahemi M, Esmaily H, Arjmand A, Pourahmad J. Mitochondrial transplantation attenuates toxicity in rat renal proximal tubular cells caused by Favipiravir. J Pharm Pharmacol [Internet]. 2023; Available from: DOI:

Hegazy SK, Tharwat S, Hassan AH. Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients. World J Clin Cases [Internet]. 2023;11(26):6105–21. Available from: DOI: